Se­duc­ing Pfiz­er: How Ar­ray’s team pa­tient­ly worked up the lad­der to win an $11.4B bid from Al­bert Bourla

Ar­ray Bio­Phar­ma CEO Ron Squar­er and his top team spent well over 2 years scout­ing for some­one to buy the com­pa­ny. And at the end of that lengthy search process a few days ago, the CEO placed the com­pa­ny in Pfiz­er’s hands for $11.4 bil­lion and will now walk away from his sales ef­fort with a for­tune worth $124.7 mil­lion for stock and $85.2 mil­lion to cov­er the gold­en para­chute.

But it wasn’t easy.

It start­ed on Jan­u­ary 23, 2017, ac­cord­ing to a new SEC fil­ing, when the com­pa­ny brought in Cen­ter­view Part­ners to be­gin the mon­ey hunt. They soon reached out to 4 like­ly buy­ers, in­clud­ing Pfiz­er, but nev­er got any­thing start­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER